Abterra Bio is enabling the next generation of antibody therapeutics. Our technologies use the latest in next-generation sequencing, mass spectrometry, and machine learning methods to comprehensively map the antibody response to challenge. We give our partners access to every relevant antibody to meet their project goals.
Alicanto® is an antibody discovery service that harnesses decades of technology development across genomics and proteomics. We use mass spectrometry and next-generation sequencing to identify high affinity monoclonal antibodies from serum. Alicanto can discovery single domain antibodies from camelids, and fully human antibodies from patients.
Reptor™ is an end-to-end solution for B-cell receptor sequencing, repertoire construction, and analysis.
Valens™ is a mass spectrometry-powered service to recover the full antibody sequence when no source cell is available.